Status:
UNKNOWN
Effectiveness and Safety of Rivaroxaban Used in Extended Anticoagulation for Pulmonary Embolism Patients
Lead Sponsor:
China-Japan Friendship Hospital
Conditions:
Pulmonary Embolism
Eligibility:
All Genders
18+ years
Brief Summary
Domestic and international guidelines for the management of pulmonary embolism have suggested that the standard duration of anticoagulation should cover at least 3 months.Whether extended anticogulati...
Detailed Description
This is a perspective, multicenter, single-arm, non-interventional, and observational study. The primary objective is to evaluate the effectiveness and safety of rivaroxaban used in extended treatment...
Eligibility Criteria
Inclusion
- Male or female adults aged 18 years or above
- Objectively confirmed diagnosis of symptomatic or asymptomatic pulmonary embolism
- Already received 6 to 12 months anticoagulant
- Indication for extend anticoagulant for at least 3 months with rivaroxaban( as assessed by the investigator)5)Written informed consent
Exclusion
- Patients with another indication for anticoagulation other than venous thromboembolism.
- Patients with contraindications listed in rivaroxaban label in china.
- Patients who participated in another study within 30 days
- Life expectation less than 3 months
Key Trial Info
Start Date :
November 30 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 30 2024
Estimated Enrollment :
496 Patients enrolled
Trial Details
Trial ID
NCT04527042
Start Date
November 30 2020
End Date
May 30 2024
Last Update
August 26 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.